GREGORY ALLEN HANKS, M.D.

Plain English
This study looked at what people with personal experience of health issues think about open research practices, like sharing data and being transparent about research methods. Out of 64 participants, most were not familiar with the term "open research," but they valued practices that promote transparency and efficiency. More than 70% of participants wanted to learn more about these practices, highlighting the need for better training and information to improve their involvement in research. Who this helps: This benefits patients and public contributors who want to be more involved in research affecting their health.

Plain English
This study looked at the listening challenges faced by autistic individuals and found that most participants reported significant difficulties, especially in noisy environments with multiple background voices. Out of 79 autistic adults surveyed, many indicated that their listening problems affected their social lives and daily interactions. Understanding these diverse listening difficulties is crucial because it can help improve research and lead to better support and interventions for autistic individuals. Who this helps: This helps autistic individuals and those who support them, like therapists and educators.

Plain English
This study looked at how Latin ballroom dance training affects walking patterns, anxiety, and depression. Researchers found that dancers had slightly different walking mechanics, with significant differences in how their legs responded when stopping. They also discovered that about 58% of dancers showed signs of anxiety, compared to only 8% of non-dancers. However, both groups had similar rates of depression. Who this helps: This information is valuable for dancers and their coaches to understand how dancing can impact mental health.

Plain English
This study looked at how fallen trees in the deep ocean connect land and sea biodiversity. Researchers found 114 different species of invertebrates living on these wood falls, with the type and size of the wood affecting which species were present. This matters because it shows that what happens to trees on land can directly impact the variety of life in the deep sea. Who this helps: This helps scientists studying ecosystems and conservation efforts focusing on both terrestrial and marine environments.

Plain English
Researchers examined how life survives in extreme conditions found in Earth's deep seas, focusing on unusual organisms known as extremophiles. They found that these creatures have unique adaptations that allow them to thrive despite extreme heat, pressure, and darkness. This understanding enhances our search for life beyond Earth, suggesting that other planets with ocean-like environments could also host life. Who this helps: This helps scientists and researchers searching for extraterrestrial life.

Plain English
This study explored how autistic adults experience hearing and understanding speech, especially in noisy environments. Nine autistic adults shared their personal challenges, revealing that many find it hard to focus on speech when there are other sounds, which can greatly affect their social lives, emotions, and work. Understanding these issues is important because many autistic individuals don't receive adequate support or recognition for their listening difficulties, which can lead to frustration and isolation. Who this helps: This research benefits autistic individuals, their families, and healthcare providers.

Plain English
This study looked at how pediatric dental specialists in the UK feel about using a local anesthetic called articaine for children, compared to the more commonly used lidocaine. Out of 61 specialists who responded, 20% said articaine is their first choice, with 62% using it regularly, especially for complex cases like infected teeth. The study found that there were significantly more adverse effects reported with lidocaine than articaine, suggesting that dentists may want to begin using articaine more often, but there are still no clear guidelines for its use in children. Who this helps: This information is beneficial for pediatric patients and their dentists.

Plain English
This study looked at how different types of biochemical failure (BF) after radiation therapy affect patient outcomes in prostate cancer. Researchers examined data from nearly 2,800 patients and found that those who had a certain type of failure (labeled A2) had significantly worse outcomes: only 74.6% survived after five years compared to 88.2% of those with the other type of failure (A1), and 29.0% of A2 patients developed distant metastasis compared to 15.7% for A1. Understanding these differences is important because it can help doctors better predict which patients might need more aggressive treatment. Who this helps: This benefits doctors and prostate cancer patients by providing clearer insights into prognosis and treatment options.

Plain English
This research paper outlines updated guidelines from the European Association for Palliative Care on how to use opioid painkillers for treating cancer pain. A panel of experts reviewed previous guidelines and current research, resulting in 16 clear recommendations for healthcare providers. This matters because it provides reliable, evidence-based strategies to help manage cancer pain effectively, improving the quality of life for patients. Who this helps: Cancer patients experiencing pain.

Plain English
This study looked at prostate cancer patients with very high PSA levels (50 ng/ml or more) to see how their outcomes compared to other high-risk patients. The results showed that patients with ultrahigh PSA levels had worse overall survival, more distant spread of cancer, and higher chances of biochemical failure; specifically, their overall survival risk was 19% higher, the risk of cancer spreading was 51% higher, and the risk of biochemical failure was 50% higher compared to other high-risk patients. This matters because it helps doctors identify which patients may need more aggressive treatment strategies based on their PSA levels at diagnosis. Who this helps: Patients with prostate cancer and their doctors.

Plain English
This study looked at how effective oxycodone is for managing pain in adults with cancer. Researchers found that oxycodone works similarly to morphine and hydromorphone in providing pain relief, and there were no significant differences in side effects between these medications. This matters because it gives doctors a reliable option for treating cancer pain, ensuring patients have access to effective pain relief. Who this helps: This helps patients with cancer who are experiencing moderate to severe pain.

Plain English
This study focused on updating guidelines for using opioids to manage cancer pain in Europe. Researchers reviewed literature from 2001 to 2008 and assessed 14 existing guidelines, creating a list of 37 important topics. After consulting with experts, they narrowed it down to 22 key topics that will inform future literature reviews and help shape the new guidelines. Who this helps: This benefits patients with cancer, ensuring they receive better pain management options.

Plain English
This study looked at over 3,000 patients in palliative care across Europe to understand how severe their non-pain symptoms were and how well these symptoms were treated. It found that common symptoms like weakness, fatigue, and anxiety affected many patients, with around 50% experiencing generalized weakness and nearly 40% not receiving treatment for issues like depression and constipation. This is important because it highlights a significant gap in care, where many patients suffer from moderate to severe symptoms without adequate treatment. Who this helps: This helps patients in palliative care by identifying areas where their symptom management can be improved.

Plain English
This research looked at how external beam radiation therapy (EBRT) affects patients with prostate cancer, focusing on long-term side effects related to the digestive and urinary systems. Out of nearly 3,000 patients followed for over 10 years, those who received short-term hormone therapy along with radiation had lower rates of severe side effects, particularly from the gastrointestinal and urinary systems. This study highlights that while radiation remains a safe option for treating high-risk prostate cancer, adding hormonal treatment can help reduce harmful side effects. Who this helps: This benefits prostate cancer patients undergoing radiation treatment.

Plain English
This study looked at who is receiving palliative care in Europe and how care is provided in different centers. Researchers collected information from 3,013 patients across 143 centers in 22 countries. They found that 94% of these patients had cancer, most were expected to live one to six months, and many received outpatient care, indicating a diverse group of patients who are not just at the end of life. This research is important because it helps better understand patient needs and promotes the development of consistent standards in palliative care. Who this helps: Patients and healthcare providers in palliative care.

Plain English
This study looked at why only a small number of cancer patients participate in clinical trials, analyzing information from over 3,000 patients who received radiation therapy for various types of cancer. It found that only 2.7% of these patients joined clinical trials, with those treated at academic hospitals and white patients being more likely to enroll compared to African American patients. This matters because improving participation in trials can lead to better treatment options for everyone, especially for underserved communities. Who this helps: This helps patients, particularly those from minority backgrounds and those treated in nonacademic settings.

Plain English
This study looked at how genetic differences in the CYP3A4 gene might affect survival rates among men with prostate cancer, particularly focusing on African American and European American patients. Researchers analyzed data from 1,514 men who underwent treatment and found that while 75% of European American men had a specific genetic variant compared to only 25% of African American men, this genetic variation did not impact overall survival or disease progression in either group. These findings are important because they indicate that genetic differences might not explain the worse outcomes often seen in African American men with prostate cancer. Who this helps: This research benefits doctors and researchers seeking to understand the factors affecting prostate cancer outcomes in different racial groups.

Plain English
This study focused on the role of a protein called p16 in men with advanced prostate cancer who were treated as part of a larger clinical trial. Researchers found that patients with high p16 levels had lower rates of cancer spreading to other parts of the body and better survival when treated with long-term hormone therapy and radiation. Specifically, high p16 patients had a significant survival improvement, while those with low p16 faced a higher risk of metastasis. Who this helps: This helps prostate cancer patients and doctors by providing insights into treatment options based on p16 levels.

Plain English
This study followed men at high risk for prostate cancer over ten years as part of a screening program. They found that out of 609 men tested, 19% had prostate biopsies, and 9% were diagnosed with prostate cancer, most of which (90%) had a Gleason score of 6 or higher, indicating meaningful cancer aggressiveness. This is important because early detection through aggressive screening can lead to better treatment outcomes, with many cancers diagnosed at lower PSA levels suggesting a higher chance of successful treatment. Who this helps: This benefits high-risk men, particularly those with a family history of prostate cancer or certain genetic mutations.

Plain English
This study looked at how age affects the treatment outcomes for men with early-stage prostate cancer who received radiation therapy. Researchers found that survival rates after five years were similar across different age groups: 94% for men 55 and younger, 95% for those aged 60 to 69, and 87% for men 70 and older. Additionally, younger men had an 82% chance of avoiding cancer-related issues, compared to 76% for middle-aged men and 70% for older men, which shows that younger patients do just as well as older ones with this treatment. Who this helps: This information benefits younger patients with prostate cancer and their doctors when considering treatment options.

Plain English
This study focused on how to define when prostate cancer treatment has failed after radiation therapy with or without hormone therapy. Researchers found that a rise in prostate-specific antigen (PSA) levels by 2 nanograms per milliliter (ng/mL) or more should be the standard way to mark biochemical failure. This updated definition is important because it improves how we track patient outcomes and ensures consistent care, ultimately helping to understand treatment effectiveness better. Who this helps: This helps patients receiving prostate cancer treatment and their doctors.

Plain English
This study looked at two treatment options for men with locally advanced prostate cancer: long-term hormone therapy for two years and short-term hormone therapy. The researchers found that long-term therapy costs about $32,564 and provides more health benefits, giving an average of 4.13 quality-adjusted life years (QALYs), compared to $33,039 and 3.68 QALYs for short-term therapy. Overall, long-term hormone therapy is not only effective but also more cost-efficient, helping patients avoid extra treatments later on. Who this helps: This helps patients with locally advanced prostate cancer and their doctors make better treatment decisions.

Plain English
This study examined how to better understand and predict the life expectancy of patients with advanced cancer. Researchers looked at 38 different studies and found strong recommendations (level A) for using clinical predictions of survival and specific prognostic scores to estimate how long patients might live, while other factors like weight loss and certain blood markers were recognized as helpful but with less certainty (level B). This matters because more accurate predictions can lead to better care and support for patients nearing the end of life. Who this helps: This helps patients and doctors by providing clearer guidance on managing advanced cancer care.

Plain English
This study looked at pain levels and treatment methods for 3,030 cancer patients in 143 palliative care centers across 21 European countries. About 32% of the patients experienced moderate to severe pain, and treatment varied significantly; for instance, morphine was the most commonly used opioid for pain relief, but its use showed large differences between countries. These findings are important because they highlight the need for consistent pain management practices to ensure that all patients receive adequate relief from their pain. Who this helps: This helps patients suffering from cancer pain and the healthcare providers who treat them.

Plain English
This study looked at what men with prostate cancer prefer when it comes to their treatment options and how different factors influence those preferences. Among 57 men who received radiation therapy, 83% had early-stage cancer, and many preferred the outcomes of radiation over surgery or hormone treatment, even as their health risks increased. Understanding these preferences helps doctors provide better personalized care for patients, which is important for decision-making in treatment. Who this helps: Patients with prostate cancer.

Plain English
This study looked at a patient with ongoing abdominal pain who was treated with pethidine, a common opioid used in UK hospitals. The researchers found that pethidine is not very strong, doesn’t last long, and can be risky to use, which highlights the problem of doctors fearing the side effects of morphine, a more effective painkiller. This fear leads to fewer patients receiving the relief they need, impacting their daily lives. Who this helps: This helps patients struggling with chronic abdominal pain.

Plain English
This study looked at how well different treatments for localized prostate cancer worked by comparing data from nearly 7,000 men treated at seven different hospitals between 1989 and 1998. It found that for men with low- and intermediate-risk cancer, the 5-year rates of prostate-specific antigen (PSA) failure were very similar, regardless of the treatment type, whereas high-risk patients had poor outcomes no matter the therapy used. These findings highlight the importance of considering multiple factors when assessing treatment effectiveness, as they can lead to better management decisions for patients. Who this helps: This helps patients with prostate cancer and their doctors in making treatment choices.

Plain English
This study looked at how the radiation treatment for localized prostate cancer compares between Caucasian men and minority men, specifically in areas with a high percentage of minority patients. Researchers found that African-American and Hispanic men tend to present with more advanced cancer stages than Caucasian men. However, when they do receive treatment, the quality of radiation therapy is similar across different groups, indicating improvements in care over the years. Who this helps: This benefits patients with prostate cancer, especially African-American and Hispanic men.

Plain English
This study looked at the outcomes for prostate cancer patients treated with radiotherapy in 1989, analyzing data from 391 patients over five years. They found that 56% of patients with early-stage cancer (T1) showed no evidence of disease five years later, while this rate dropped to 36% for those with more advanced cancer (T3/T4). Higher prostate-specific antigen (PSA) levels and Gleason scores were linked to worse outcomes, indicating that these factors are important in predicting a patient’s chance of recovery. Who this helps: This information benefits patients and doctors by providing insights into treatment effectiveness based on cancer stage and PSA levels.

Plain English
This study examined how consistently 20 expert doctors could assign stages to prostate cancer cases using the American Joint Committee on Cancer (AJCC) system from 1992. It found that experts agreed on the T stage only 63.9% of the time, the N stage 73.8%, and the M stage 76.6%. These inconsistencies show that the current staging system may not accurately reflect the disease's severity, which is important for ensuring patients receive the right treatment. Who this helps: This benefits patients by highlighting the need for more accurate staging to guide their treatment options.

Plain English
This study looked at changes in prostate cancer markers, including PSA levels and disease stage, among different racial groups and regions over the past decade. Researchers analyzed data from nearly 6,800 patients, finding that PSA levels dropped overall by 0.8% each year, with a sharper decline of 1.9% per year in African-American patients compared to 0.6% in white patients. These trends indicate that prostate cancer characteristics are changing, which is particularly positive for African-American patients, as they now have more favorable conditions before treatment. Who this helps: This information benefits patients, especially those with prostate cancer, as well as doctors treating them.

Plain English
This study looked at how effective 3D conformal radiation therapy (3DCRT) is for treating high-grade prostate cancer patients, specifically those with more aggressive tumors. Out of 180 patients analyzed, after 5 years, 62.5% managed to avoid rising PSA levels, with success rates reaching 79.3% for those with earlier-stage tumors. The findings indicate that giving higher doses of radiation (over 70 Gy) is important for better outcomes, highlighting the importance of tailored treatment plans for patients with aggressive prostate cancer. Who this helps: This helps patients with high-grade prostate cancer and their doctors in making informed treatment decisions.

Plain English
This study focused on how to manage chronic pain and intestinal blockages in patients with terminal cancer. Researchers found that a straightforward method using oral medications can effectively control pain in about 80% of these patients. This matters because it highlights a way to significantly improve the quality of life for those facing severe illness. Who this helps: Patients with terminal cancer.

Plain English
This study focused on creating clear treatment guidelines for patients with rectal cancer, specifically those with a type called adenocarcinoma. The researchers gathered experts in cancer treatment and reviewed existing studies to reach an agreement on the best approaches. They evaluated four major treatment scenarios and categorized options as acceptable or not, ultimately developing a decision tree to aid in treatment choices. This matters because having clear guidelines can improve patient care and outcomes. Who this helps: This helps patients with rectal cancer and their doctors.

Plain English
This study looked at how rectal cancer patients in the US are treated with radiation therapy. Out of 507 patients surveyed, 75% received radiation after surgery, and 90% were given chemotherapy for about 21 weeks. While many patients benefited from advanced radiation techniques, only 7% participated in clinical trials, but those trials still positively impacted treatment practices. Who this helps: This helps rectal cancer patients and their doctors understand current treatment standards and options.

Plain English
This research looked at the effectiveness of dexamethasone, a type of steroid, for relieving bowel blockages caused by cancer. Out of 35 patients, 60% responded positively to treatment by the fifth day, but only 13 were on dexamethasone and 8 on a placebo, making it unclear if the drug really works. The studies struggled with getting enough participants, so researchers couldn’t confirm if dexamethasone is truly effective for this issue. Who this helps: This research is important for doctors treating patients with bowel obstruction due to cancer.

Plain English
This study looked at the effects of higher radiation doses on prostate cancer patients with low pretreatment PSA levels (below 10 ng/ml). Researchers found that increasing the radiation dose did not lead to better outcomes in terms of lower PSA levels or cancer control rates after three years; specifically, there was no significant change in achieving a PSA level below 1 ng/ml or in cancer control. This matters because it suggests that giving more radiation may not provide additional benefits and could increase side effects without improving patient outcomes. Who this helps: This helps prostate cancer patients with low pretreatment PSA levels and their doctors make better treatment decisions.

Plain English
This study examined how adenocarcinoma, a type of cancer in the rectum and sigmoid colon, is treated across different facilities in the U.S. Researchers compared data from 73 radiation therapy centers to established treatment guidelines from 1989 and 1990. They found that many treatment practices did not align with the recommended guidelines, highlighting gaps in care that could impact patient outcomes. Who this helps: This information benefits patients with rectal and sigmoid adenocarcinoma by identifying areas for improvement in their treatment.

Plain English
This study investigated how a special inflatable leg brace helps athletes recover from tibial stress fractures faster than standard treatment. Athletes using the brace returned to light activity in about 7 days compared to 21 days for those using traditional methods, and they achieved full activity in about 21 days, while the traditional group took around 77 days. This finding is important because it means that athletes can get back to sports much sooner with the brace. Who this helps: Athletes recovering from tibial stress fractures.